NBY Novabay Pharmaceuticals Inc.
- 0 P/E
- 31.27 P/S
- 5.86 P/B
- -0.317 EPS
- -2,345.19% Cash ROIC
- 3.60 Cash Ratio
- 0 / 0% Dividend
- 134,627.00 Avg. Vol.
- 38.18M Shares
- 32.5M Market Cap.
NovaBay Pharmaceuticals Inc., a clinical stage biotechnology company, engages in developing proprietary and patented topical Aganocide compounds for the treatment and prevention of various infections without causing bacterial resistance. Its Aganocide compounds are synthetic anti-infective product candidates with equivalent activity to the active antimicrobial molecules generated within white bloo...
GlobeNewswire (press release) - Nov 12, 2014
The Wall Street Transcript - Dec 8, 2014
Seeking Alpha (registration) - Aug 20, 2014
sleekmoney - Dec 15, 2014
GlobeNewswire (press release) - Mar 20, 2014
The Legacy - Dec 17, 2014
Business Wire (press release) - Oct 27, 2014
ACN Newswire (press release) - Dec 16, 2014
Yahoo News - Oct 14, 2014
Seeking Alpha - Dec 9, 2013